Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06276868 | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | recruiting | Phase 2 | 71 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06723899 | Testing the Effectiveness of a Work Rehabilitation Intervention for Women with Breast Cancer(CanWork) | recruiting | N/A | 248 | University of Dublin, Trinity CollegeOTHER | 1 | Dec 17, 2024 |
| clinicaltrials |
| NCT06738459 | Precision Retrospective Integrative Study for Metastatic Lymph Nodes in Breast Cancer(PRISM) | recruiting | — | 1,500 | Centro di Riferimento Oncologico - AvianoOTHER | 2 | Dec 17, 2024 | clinicaltrials |
| NCT04170634 | Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study(MEKANOS) | recruiting | — | 220 | Hospices Civils de LyonOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06636981 | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05974449 | Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients | recruiting | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05989776 | Increasing Access to Fertility Preservation for Women with Breast Cancer(EVAPREF) | recruiting | N/A | 750 | University Paul Sabatier of ToulouseOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | recruiting | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06602167 | Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome | recruiting | N/A | 220 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06180642 | Reliability and Validity of Ultrasound for the Assessment of Soft Tissue Properties After Breast Cancer Treatment(SOFT-TI) | recruiting | — | 90 | Universiteit AntwerpenOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06727487 | OvS Breast: Ovarian Suppression in Breast Cancer Interventions(ENBI) | recruiting | N/A | 30 | Universidad Pontificia ComillasOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06728527 | PARTial BREast RECONstruction With Chest Wall Perforator Flap(PartBreCon) | recruiting | — | 1,001 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06729684 | Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors | recruiting | N/A | 72 | Samsung Medical CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06703567 | IMproving PAtient UndeRstanding of GEP TEst Results: Phase 4(IMPARTER) | recruiting | N/A | 82 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06725082 | Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery(ColBreast) | recruiting | Phase 1 | 30 | Peking University People's HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04590560 | What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?(MISS) | recruiting | N/A | 60,000 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06236373 | The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia(Survivorship) | recruiting | — | 45 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722599 | Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients(LRNacHER2) | recruiting | — | 171 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722612 | Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer(TaxCbHER2) | recruiting | — | 2,916 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04616300 | Exercise and Cognitive (Brain) Function in Breast Cancer Patients Getting Chemotherapy After Breast Surgery | recruiting | — | 50 | University of TorontoOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06717984 | AI Model for Classifying Breast Cancer From Histopathology Images | recruiting | — | 500 | Taufiq Hasan, PhDOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06304857 | CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL(PROTECTAA) | recruiting | Phase 3 | 188 | 4th Military Clinical Hospital with Polyclinic, PolandOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06713161 | Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status(NIR-II) | recruiting | — | 40 | Yunnan Cancer HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06401005 | SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) | recruiting | Phase 2 | 51 | Hubei Cancer HospitalOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711055 | Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer(TaxHER) | recruiting | — | 285 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711068 | Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy(TaxDHER2) | recruiting | — | 8,077 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711185 | Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy(DAPA-MYOCANCER) | recruiting | Phase 3 | 80 | University of Campinas, BrazilOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05440149 | The Postoperative Radiotherapy in N1 Breast Cancer Patients(PORT-N1) | recruiting | Phase 3 | 1,106 | Seoul National University HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03536897 | IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry | recruiting | — | 168 | Mount Carmel Health SystemOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05891561 | Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | recruiting | Phase 2 | 120 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05512286 | Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction(CAPPELLA) | recruiting | N/A | 80 | Fudan UniversityOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06102824 | Organoid-based Functional Precision Therapy for Advanced Breast Cancer(ORIENTA) | recruiting | Phase 2 | 252 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06222879 | Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 350 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06700369 | De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients(NacHER2) | recruiting | — | 519 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06700382 | Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC(NeoTNBCX) | recruiting | — | 1,166 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06587789 | Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer | recruiting | — | 286 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06698679 | The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer | recruiting | — | 1,000 | Shengjing HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06692725 | De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC(NacTNBC) | recruiting | — | 380 | Peking University People's HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693024 | Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer(NeraHER2) | recruiting | — | 2,806 | Shu WangOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693037 | Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy(nonPHER) | recruiting | — | 2,092 | Shu WangOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06697938 | Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study(NCRT-LABC) | recruiting | N/A | 148 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03971045 | Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer(PERICLES) | recruiting | Phase 2 | 46 | European Institute of OncologyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05217966 | Single Pre-Operative Radiation Therapy - With Delayed or No Surgery (SPORT-DNS)(SPORT-DNS) | recruiting | N/A | 80 | Maisonneuve-Rosemont HospitalOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06044623 | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients(IMPORTANT) | recruiting | Phase 3 | 495 | Region Örebro CountyOTHER | 6 | Nov 19, 2024 | clinicaltrials |
| NCT06222957 | The Effects of HER2 Receptor Signaling on Human Brown Fat Activity(HEAT) | recruiting | — | 30 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06252662 | Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies | recruiting | Phase 4 | 200 | United States Naval Medical Center, PortsmouthFED | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06452706 | The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | recruiting | Phase 2 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05933876 | The Impact of Radiotherapy on Oligometastatic Cancer | recruiting | — | 2,000 | Institut Investigacio Sanitaria Pere VirgiliOTHER | 1 | Nov 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2024source: clinicaltrials